More articles from Interstitial lung disease

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
Lavanya Raman, Iain Stewart, Shaney L. Barratt, Felix Chua, Nazia Chaudhuri, Anjali Crawshaw, Michael Gibbons, Charlotte Hogben, Rachel Hoyles, Vasilis Kouranos, Jennifer Martinovic, Sarah Mulholland, Katherine J. Myall, Marium Naqvi, Elisabetta A. Renzoni, Peter Saunders, Matthew Steward, Dharmic Suresh, Muhunthan Thillai, Athol U. Wells, Alex West, Jane A. Mitchell, Peter M. George

ERJ Open Research Mar 2023, 9 (2) 00423-2022; DOI: 10.1183/23120541.00423-2022
Developing a self-management package for pulmonary fibrosis: an international Delphi study
Joanna Y.T. Lee, Gabriella Tikellis, Yet H. Khor, Anne E. Holland

ERJ Open Research Oct 2022, 8 (4) 00349-2022; DOI: 10.1183/23120541.00349-2022
Development and validation of an interstitial lung disease exposure questionnaire for sub-Saharan Africa
Peter Jackson, Roma Padalkar, Winceslaus Katagira, Kevin Mortimer, Natalie A. Rykiel, Nicole M. Robertson, Suzanne L. Pollard, Patricia Alupo, William Checkley, Bruce Kirenga, Trishul Siddharthan

ERJ Open Research Oct 2022, 8 (4) 00205-2022; DOI: 10.1183/23120541.00205-2022
Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
Hirokazu Urushiyama, Taisuke Jo, Wakae Hasegawa, Akira Yokoyama, Takahiro Ando, Yukiyo Sakamoto, Ryosuke Kumazawa, Kazuaki Uda, Nobuaki Michihata, Nobuyasu Awano, Matsui Hiroki, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase

ERJ Open Research Oct 2022, 8 (4) 00209-2022; DOI: 10.1183/23120541.00209-2022
Neighbourhood disadvantage impacts on pulmonary function in patients with sarcoidosis
Gillian C. Goobie, Christopher J. Ryerson, Kerri A. Johannson, Spencer Keil, Erin Schikowski, Nasreen Khalil, Veronica Marcoux, Deborah Assayag, Hélène Manganas, Jolene H. Fisher, Martin R.J. Kolb, Xiaoping Chen, Kevin F. Gibson, Daniel J. Kass, Yingze Zhang, Kathleen O. Lindell, S. Mehdi Nouraie

ERJ Open Research Oct 2022, 8 (4) 00357-2022; DOI: 10.1183/23120541.00357-2022
Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra
Koji Kuronuma, Natsumi Susai, Tomohiro Kuroita, Hiroki Yamamoto, Takeshi Yoshioka, Shuji Kaneko, Hirofumi Chiba

ERJ Open Research Oct 2022, 8 (4) 00245-2022; DOI: 10.1183/23120541.00245-2022
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz

ERJ Open Research Oct 2022, 8 (4) 00240-2022; DOI: 10.1183/23120541.00240-2022
Matrix metalloproteinase-7 is increased in lung bases but not apices in idiopathic pulmonary fibrosis
Jade Jaffar, Mae Wong, Gregory A. Fishbein, Monther Alhamdoosh, Laura McMillan, Cristina Gamell-Fulla, Milica Ng, Nick Wilson, Karen Symons, Ian Glaspole, Glen Westall

ERJ Open Research Oct 2022, 8 (4) 00191-2022; DOI: 10.1183/23120541.00191-2022
Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohort
Heba M. Bintalib, David M. Lowe, Gaia Mancuso, Georgia Gkrepi, Suranjith L. Seneviratne, Siobhan O. Burns, John R. Hurst

ERJ Open Research Oct 2022, 8 (4) 00024-2022; DOI: 10.1183/23120541.00024-2022
Functional clinical impairments and frailty in interstitial lung disease patients
Pierre-François Tremblay Labrecque, Geneviève Dion, Didier Saey

ERJ Open Research Oct 2022, 8 (4) 00144-2022; DOI: 10.1183/23120541.00144-2022

Main menu

User menu

Search

More articles from Interstitial lung disease

Pages

Contact us